Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto- oncogene

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 2, 1998, Pages 487-491

  Schuffenecker, Isabelle ^a,n   Virally Monod, Marie ^b   Brohet, Richard ^c   Goldgar, David ^c   Conte Devolx, Bernard ^d   Leclerc, Laurence ^e   Chabre, Olivier ^f   Boneu, Andree ^g   Caron, Jean ^h   Houdent, Chantal ⁱ   Modigliani, Elisabeth ^j   Rohmer, Vincent ^k   Schlumberger, Martin ^l   Eng, Charis ^m,o   Guillausseau, Pierre Jean ^b   Lenoir, Gilbert Marcel ^a  

^a UNIVERSITÉ LYON 1   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j AVICENNE HOSPITAL   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l INSTITUT GUSTAVE ROUSSY   (France)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ CNRS   (France)

^o Ctr Natl de la Rech Scientifique ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CODON; FEMALE; GENE MUTATION; GERM LINE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; PENETRANCE; PREVALENCE; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME;

ADULT; AGING; CODON; DROSOPHILA PROTEINS; HUMANS; HYPERPARATHYROIDISM; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PENETRANCE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS;

EID: 15144343501     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.2.487     Document Type: Article

References (32)

1. Ponder BAJ. 1995 Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. In: Imperial Cancer Research Foundation, ed. Cancer Surveys. Vol 25. Oxford: Oxford University Press; 195-204.
2. Donovan DT, Gagel RF. 1990 Medullary thyroid carcinoma and the multiple endocrine neoplasia syndromes. In: Falk SA, ed. Thyroid disease: endocrinology, surgery, nuclear medicine, and radiotherary. New York: Raven Press, Ltd; 501-525.
3. Kraimps JL, Barbier J. 1992 Primary hyperparathyroidism and multiple endocrine neoplasia. In: Barbier J, Henry JF, eds. Primary hyperparathyroidism. Paris: Springer-Verlag; 131-138.
4. Howe JR, Norton JA, Wells Jr SA. 1993 Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of longterm follow-up. Surgery. 114:1070-1077.
5. Gagel RF. 1994 Clinical management of parathyroid disease in MEN 2. In: Bilezikian JP, Lewine LA, Marcus R, eds. The parathyroids. New York: Raven Press, Ltd; 681-698.
6. O'Riordan DS, O'Brien T, Grant CS, et al. 1993 Surgical management of primary hyperparathyroidism in multiple endocrine neoplasias type 1 and 2. Surgery. 114:1031-1039.
7. Raue F, Kraimps JL, Cougard P, et al. 1995 Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med. 238:369-373.
8. Kraimps JL, Denizot A, Carnaille B, et al. 1996 Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. A retrospective French multicentric study on 56 cases by the GETC. World J Surg. 20:808-813.
9. Mallette LE. 1994 Management of hyperparathyroidism in the multiple endocrine neoplasia syndromes and other familial endocrinopathies. Endocrinol Metab Clin North Am. 23:137-156.
10. Durbec P, Marcos-Gutierrez CV, Kilkenny C, et al. 1996 GDNF signalling through the RET receptor tyrosine kinase. Nature. 381:789-793.
11. Jing S, Weng D, Yu Y, et al. 1996 GDNF-induced activation of the RET protein kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell. 85:1113-1124.
12. Trupp M, Arenas E, Fainzilber M, et al. 1996 Functional receptor for glial cell line-derived neurotrophic factor (GDNF) encoded by the c-ret proto-oncogene. Nature. 381:785-789.
13. Carlson KM, Dou S, Chi D, et al. 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA. 91:1579-1583.
14. Eng C, Smith DP, Mulligan LM, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 3:237-241.
15. Hofstra RMW, Landsvater RM, Ceccherini I, et al. 1994 Mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:375-376.
16. Rossel M, Schuffenecker I, Schlumberger M, et al. 1995 Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet. 95:403-406.
17. Eng C, Clayton D, Schuffenecker I, et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA. 276:1575-1579.
18. Mulligan LM, Kwok JBJ, Healey CS, et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363:458-460.
19. Mulligan LM, Eng C, Healey CS, et al. 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 6:70-74.
20. Schuffenecker I, Billaud M, Calender A, et al. 1994 RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet. 3:1939-1943.
21. Eng C, Smith DP, Mulligan LM, et al. 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 10:509-513.
22. Bolino A, Schuffenecker I, Luo Y, et al. 1995 RET mutations in exons 13 and 14 patients. Oncogene. 10:2415-2419.
23. Santoro M, Carlomagno F, Romano A, et al. 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 267:381-383.
24. Asai N, Iwashita T, Matsuyama M, Takahashi M. 1995 Mechanism of activation of the Ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 15:1613-1619.
25. Borrello MG, Smith DP, Pasini B, et al. 1995 RET activation by germline MEN2A and MEN2B mutations. Oncogene. 11:2419-2427.
26. Rossel M, Pasini A, Chappuis S, et al. 1997 Distinct biological properties of two RET isoforms activated by MEN2A/FMTC and MEN2B mutations. Oncogene. 14:265-275.
27. Pasini A, Geneste O, Legrand P, et al. 1997 Oncogenic activation of RET by two distinct mutations affecting the tyrosine kinase domain. Oncogene. 15:393-402.
28. Frank-Raue K, Höppner W, Frilling A, et al. 1996 Mutations of the Ret proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab. 81:1780-1783.
29. McMahon R, Mulligan LM, Healey CS, et al. 1994 Direct non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Hum Mol Genet. 3:643-646.
30. Lips CJM, Landsvater RM, Höppener JWM, et al. 1994 Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 29:828-835.
31. Ledger GA, Khosla S, Lindor NM, et al. 1995 Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med. 122:118-124.
32. Conte-Devolx B, Schuffenecker I, Niccoli P, et al. 1997 Multipe endocrine neoplasia type 2: management of patients and subjects at-risk. Horm Res. 47:221-226.